Delayed corneal epithelial healing after intravitreal bevacizumab: A clinical and experimental study

Journal of Ophthalmic and Vision Research

Volumn 6, Issue 1, 2011, Pages 18-25

  Colombres, Gustavo A ^a   Gramajo, Ana L ^a   Arrambide, Maria P ^a   Juarez, Silvina M ^a   Fernando Arevalo, J ^b   Bar, Jorge ^c   Juarez, Claudio P ^a   Luna, Jose D ^a  

^a Fundacion VER   (Argentina)

^b Clinica Oftalmologica Centro Caracas   (Venezuela)

^c Hospital Nacional de Clínicas   (Argentina)

Author keywords

Antiangiogenics; Complications; Corneal edema; Corneal epithelial defect; Intravitreal bevacizumab

Indexed keywords

EID: 79951572894     PISSN: 20082010     EISSN: 2008322X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
2. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-868.
3. Vinores SA, Youssri AI, Luna JD, Chen YS, Bhargave S, Vinores MA, et al. Upregulation of vascular endothelial growth factor in ischemic and nonischemic human and experimental retinal disease. Histol Histopathol 1997;12:99-109.
4. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999;40:182-189.
5. Funatsu H, Yamashita H, Nakamura S, Mimura T, Eguchi S, Noma H, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006;113:294-301.
6. Lu M, Adamis AP. Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. Ophthalmol Clin North Am 2002;15:69-79.
7. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
8. Campochiaro PA. Ocular neovascularisation and excessive vascular permeability. Expert Opin Biol Ther 2004;4:1395-1402.
9. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006;142:660-668.
10. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354.
11. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
12. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
13. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-4578.
14. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
15. Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res 2000;19:113-129.
16. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea 2008;27:70-73.
17. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007;125:834-836.
18. Bock F, Konig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008;246:281-284.
19. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 2008;33:23-28.
20. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993-997.
21. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87.
22. Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 2008;28:1151-1158.
23. Kenyon KR. The synthesis of basement membrane by the corneal epithelium in bullous keratopathy. Invest Ophthalmol 1969;8:156-168.
24. Ljubimov AV, Burgeson RE, Butkowski RJ, Couchman JR, Wu RR, Ninomiya Y, et al. Extracellular matrix alterations in human corneas with bullous keratopathy. Invest Ophthalmol Vis Sci 1996;37:997-1007.
25. Boon CJ, Crama N, Klevering BJ, van Kuijk FJ, Hoyng CB. Reflux after intravitreal injection of bevacizumab. Ophthalmology 2008;115:1270.
26. Chang SW, Chou SF, Chuang JL. Mechanical corneal epithelium scraping and ethanol treatment upregulate cytokine gene expression differently in rabbit cornea. J Refract Surg 2008;24:150-159.
27. Jester JV, Huang J, Fisher S, Spiekerman J, Chang JH, Wright WE, et al. Myofibroblast differentiation of normal human keratocytes and hTERT, extendedlife human corneal fibroblasts. Invest Ophthalmol Vis Sci 2003;44:1850-1858.
28. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557-563.
29. Wilson SE, Ambrosio R. Laser in situ keratomileusisinduced neurotrophic epitheliopathy. Am J Ophthalmol 2001;132:405-406.
30. Murphy CJ, Marfurt CF, McDermott A, Bentley E, Abrams GA, Reid TW, et al. Spontaneous chronic corneal epithelial defects (SCCED) in dogs: clinical features, innervation, and effect of topical SP, with or without IGF-1. Invest Ophthalmol Vis Sci 2001;42:2252-2261.
31. Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 1999;19:5731-5740.
32. Yu CQ, Zhang M, Matis KI, Kim C, Rosenblatt MI. Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci 2008;49:3870-3878.
33. Vigneault F, Zaniolo K, Gaudreault M, Gingras ME, Guérin SL. Control of integrin genes expression in the eye. Prog Retin Eye Res 2007;26:99-161.
34. Kim TI, Chung JL, Hong JP, Min K, Seo KY, Kim EK. Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 2009;50:4653-4659.
35. Masur SK, Cheung JK, Antohi S. Identification of integrins in cultured corneal fibroblasts and in isolated keratocytes. Invest Ophthalmol Vis Sci 1993;34:2690-2698.
36. Soro S, Orecchia A, Morbidelli L, Lacal PM, Morea V, Ballmer-Hofer K, et al. A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha5beta1 integrin. Blood 2008;111:3479-3488.